Premium
EPH receptor/ephrin system: in the quest for novel anti‐angiogenic therapies: Commentary on Hassan‐Mohamed et al ., Br J Pharmacol 171: 5195–5208
Author(s) -
Hatziapostolou M,
Polytarchou C
Publication year - 2015
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12718
Subject(s) - erythropoietin producing hepatocellular (eph) receptor , ephrin , antagonist , in vitro , medicine , angiogenesis , receptor , pharmacology , chemistry , biochemistry , receptor tyrosine kinase
Linked Article This article is a Commentary on Hassan‐Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph‐ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195–5208. doi: 10.1111/bph.12669